Država: Južnoafriška republika
Jezik: angleščina
Source: South African Health Products Regulatory Authority (SAHPRA)
Zoetis South Africa (Pty) Ltd
See ingredients
Injection
Each 1.0 ml Solution contains CARPROFEN A 50.0 mg
C 3.1.1 Steroidals
Registered
2009-03-08
_ _ Page 1 of 5 _ _ PACKAGE INSERT VETERINARY MEDICINE SCHEDULING STATUS PROPRIETARY NAME AND DOSAGE FORM RIMADYL Aqueous Injection (Injection) COMPOSITION Each ml contains 50 mg carprofen. Preservatives: Ethanol 0,1 mg/ml and benzylalcohol 10 mg/ml. PHARMACOLOGICAL CLASSIFICATION C 3.1.2.2 NSAIDs, Selective COX2 inhibitors PHARMACOLICAL ACTION: Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity. The exact mode of action of carprofen has not been established, however, inhibition of prostaglandin synthesis accounts for at least part of its mechanism of action. Carprofen is a moderately potent inhibitor of phospholipase A 2 and a reversible inhibitor of cyclo-oxygenase (COX). In _ in-vitro_ cell-culture of canine origin, carprofen displayed selectivity for COX-2, the inducible form of the enzyme upregulated in damaged and inflamed tissue, compared with its inhibition of COX-1, the iso-enzyme which is involved in normal gastric function. Carprofen has also been shown to inhibit the release of prostaglandins in acute polymorphonuclear leukocyte and chronic inflammatory reactions. Carprofen has modulatory effects on both humoral and cellular immune responses. It inhibits the production of osteoclast-activating factor (OAF), PGE 1 , and PGE 2 , by its inhibitory effects on prostaglandin biosynthesis. PHARMACOKINETIC PROPERTIES AND PHARMACODYNAMIC PROPERTIES Calves below 12 months of age: S3 _ _ Page 2 of 5 _ _ Carprofen exhibits age dependent pharmacokinetics, such that the half-life in calves with mean bodyweight of 68 kg is approximately 111 hours which is decreased to approximately half that value (61 hours), for calves with a mean bodyweight of 90 kg and beyond. Despite this, no difference has been seen in the duration of clinical efficacy in young cattle between 1 and 48 weeks of age. In a study in calves of thirteen weeks of age the following kinetic parameters were determined: Absorption: Following a single subcutaneous injection of 1,4 mg/kg Preberite celoten dokument